Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Medical School

David Geffen School of Medicine at UCLA

2013, Los Angeles, CA

Internship

Boston Children's Hospital

2014, Boston, MA

Residency

Boston Children's Hospital

2016, Boston, MA

Fellowship

Boston Children's Hospital

2019, Boston, MA

Certifications

  • American Board of Pediatrics (General)
  • American Board of Pediatrics (Rheumatology)

Publications

  1. Sex Differences in B Cells From the Joints of Children With Oligoarticular Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2025 Mar 17. View Abstract

  2. Implementation study of the CARRA Uveitis Consensus Treatment Plans: feasibility for clinical practice and applicability for research. Pediatr Rheumatol Online J. 2024 Oct 07; 22(1):88. View Abstract

  3. Severe Features of Systemic Juvenile Idiopathic Arthritis in Patients With Congenital Heart Disease. J Rheumatol. 2024 Aug 01; 51(8):811-817. View Abstract

  4. Joint-specific memory, resident memory T cells and the rolling window of opportunity in arthritis. Nat Rev Rheumatol. 2024 May; 20(5):258-271. View Abstract

  5. Elevation of IL-17 Cytokines Distinguishes Kawasaki Disease From Other Pediatric Inflammatory Disorders. Arthritis Rheumatol. 2024 02; 76(2):285-292. View Abstract

  6. Type I interferon signature and cycling lymphocytes in macrophage activation syndrome. J Clin Invest. 2023 11 15; 133(22). View Abstract

  7. Development of a Screening Algorithm for Lung Disease in Systemic Juvenile Idiopathic Arthritis. ACR Open Rheumatol. 2023 Oct; 5(10):556-562. View Abstract

  8. Incidence and Risk Factors for Eosinophilia and Lung Disease in Biologic-Exposed Children With Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). 2023 10; 75(10):2063-2072. View Abstract

  9. Disordered T cell-B cell interactions in autoantibody-positive inflammatory arthritis. Front Immunol. 2022; 13:1068399. View Abstract

  10. mTORC1 links pathology in experimental models of Still's disease and macrophage activation syndrome. Nat Commun. 2022 11 28; 13(1):6915. View Abstract

  11. Joint-Specific Memory and Sustained Risk for New Joint Accumulation in Autoimmune Arthritis. Arthritis Rheumatol. 2022 11; 74(11):1851-1858. View Abstract

  12. An Evidence-Based Guideline Improves Outcomes for Patients With Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome. J Rheumatol. 2022 Sep; 49(9):1042-1051. View Abstract

  13. Proteomics based markers of clinical pain severity in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2022 Jan 15; 20(1):3. View Abstract

  14. Weekly Adalimumab, an Effective Alternative for Refractory Uveitis in Children. J Clin Rheumatol. 2022 Jan 01; 28(1):e301-e304. View Abstract

  15. Arthritis flares mediated by tissue-resident memory T cells in the joint. Cell Rep. 2021 10 26; 37(4):109902. View Abstract

  16. Th1 polarization defines the synovial fluid T cell compartment in oligoarticular juvenile idiopathic arthritis. JCI Insight. 2021 09 22; 6(18). View Abstract

  17. IL-1ß-driven osteoclastogenic Tregs accelerate bone erosion in arthritis. J Clin Invest. 2021 09 15; 131(18). View Abstract

  18. Uveitis in Children and Adolescents. Rheum Dis Clin North Am. 2021 11; 47(4):619-641. View Abstract

  19. A multidisciplinary assessment of pain in juvenile idiopathic arthritis. Semin Arthritis Rheum. 2021 08; 51(4):700-711. View Abstract

  20. Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms. Pediatr Rheumatol Online J. 2021 Mar 17; 19(1):31. View Abstract

  21. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest. 2020 11 02; 130(11):5942-5950. View Abstract

  22. Identification of Prevotella Oralis as a possible target antigen in children with Enthesitis related arthritis. Clin Immunol. 2020 07; 216:108463. View Abstract

  23. Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis. JCI Insight. 2020 03 26; 5(6). View Abstract

  24. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2020 02; 79(2):225-231. View Abstract

  25. Antibody-dependent and -independent mechanisms of inflammatory arthritis. JCI Insight. 2019 03 07; 4(5). View Abstract

  26. Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr Rheumatol Online J. 2019 Feb 14; 17(1):7. View Abstract

  27. Megakaryocytes compensate for Kit insufficiency in murine arthritis. J Clin Invest. 2017 May 01; 127(5):1714-1724. View Abstract

  28. Galectin-1 regulates tissue exit of specific dendritic cell populations. J Biol Chem. 2015 Sep 11; 290(37):22662-77. View Abstract

  29. Glucose metabolism is required for oxidized LDL-induced macrophage survival: role of PI3K and Bcl-2 family proteins. Arterioscler Thromb Vasc Biol. 2009 Sep; 29(9):1283-9. View Abstract

  30. Galectin-1 co-clusters CD43/CD45 on dendritic cells and induces cell activation and migration through Syk and protein kinase C signaling. J Biol Chem. 2009 Sep 25; 284(39):26860-70. View Abstract

  31. MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation. Blood. 2009 Jul 09; 114(2):404-14. View Abstract

  32. Phosphatidylinostitol-3 kinase and phospholipase C enhance CSF-1-dependent macrophage survival by controlling glucose uptake. Cell Signal. 2009 Sep; 21(9):1361-9. View Abstract

  33. beta-Adrenoreceptors reactivate Kaposi's sarcoma-associated herpesvirus lytic replication via PKA-dependent control of viral RTA. J Virol. 2005 Nov; 79(21):13538-47. View Abstract
BESbswy